Meghalaya Magazine

Chronic Kidney Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Tricida, Otsuka Pharmaceuticals, AstraZeneca

 Breaking News
  • No posts were found

Chronic Kidney Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Tricida, Otsuka Pharmaceuticals, AstraZeneca

October 06
18:08 2022
Chronic Kidney Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Tricida, Otsuka Pharmaceuticals, AstraZeneca
The Chronic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Insights

 

Chronic Kidney Disease Overview 

Chronic kidney disease (CKD) is defined by reduced estimated glomerular filtration rate (eGFR <60ml/min/1.73m2) or kidney damage (usually detected by high albuminuria ≥30 mg albumin per gram of creatinine). According to CDC, Chronic kidney disease is estimated to affect 10 to 15% of adults in the US, Europe and Asia.

 

Some of the key facts of the Chronic Kidney Disease Market Report:  

  • The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • According to Cheng et al., the global estimated prevalence of Chronic Kidney Disease is 13.4% (11.7–15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated between 4.902 and 7.083 million 
  • According to Center of Disease control and Prevention, Chronic Kidney Disease is more common in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%) 
  • Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others 
  • Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others 
  • The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%) 

 

Get a Free sample for the Chronic Kidney Disease Market Report 

 

Key benefits of the Chronic Kidney Disease Market report:

  1. Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Chronic Kidney Disease Epidemiology and Chronic Kidney Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Chronic Kidney Disease market report provides insights on the current and emerging therapies.
  3. Chronic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Chronic Kidney Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Chronic Kidney Disease market.

 

Chronic Kidney Disease Epidemiology Segmentation:

The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Kidney Disease
  • Prevalent Cases of Chronic Kidney Disease by severity
  • Gender-specific Prevalence of Chronic Kidney Disease
  • Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease 

 

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiological Insights

 

Chronic Kidney Disease Market  

The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function.”

 

Chronic Kidney Disease Therapies and Key Companies

  • TRC101 (Veverimer): Tricida
  • Tolvaptan: Otsuka Pharmaceuticals
  • AZD5718: AstraZeneca

 

Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease market forecast

 

Scope of the Chronic Kidney Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
  • Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
  • Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
  • Chronic Kidney Disease Market Dynamics:  Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Kidney Disease Market Access and Reimbursement 

 

Table of Contents 

1. Chronic Kidney Disease Market Report Introduction

2. Executive Summary for Chronic Kidney Disease

3. SWOT analysis of Chronic Kidney Disease

4. Chronic Kidney Disease Patient Share (%) Overview at a Glance

5. Chronic Kidney Disease Market Overview at a Glance

6. Chronic Kidney Disease Disease Background and Overview

7. Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Kidney Disease 

9. Chronic Kidney Disease Current Treatment and Medical Practices

10. Chronic Kidney Disease Unmet Needs

11. Chronic Kidney Disease Emerging Therapies

12. Chronic Kidney Disease Market Outlook

13. Country-Wise Chronic Kidney Disease Market Analysis (2019–2032)

14. Chronic Kidney Disease Market Access and Reimbursement of Therapies

15. Chronic Kidney Disease Market Drivers

16. Chronic Kidney Disease Market Barriers

17.  Chronic Kidney Disease Appendix

18. Chronic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com